Halozyme Therapeutics reported $64.12M in Cost of Sales for its fiscal quarter ending in June of 2025.


Cost Of Sales Change Date
Acadia Pharmaceuticals USD 20.73M 342K Jun/2025
Agios Pharmaceuticals USD 1.7M 617K Jun/2025
Alnylam Pharmaceuticals USD 142.95M 71.91M Jun/2025
Amarin USD 16.89M 18.51M Mar/2025
Amgen USD 3.01B 406M Jun/2025
Baxter International USD 1.82B 55M Jun/2025
Cytokinetics 112.55M 12.71M Jun/2025
Eli Lilly USD 2.45B 223.6M Jun/2025
Halozyme Therapeutics USD 64.12M 15.72M Jun/2025
Ionis Pharmaceuticals USD 4.15M 3.15M Jun/2025
MannKind USD 20.57M 3.55M Jun/2025
Pfizer USD 4.99B 2.4B Jun/2025
United Therapeutics USD 175.2M 102.3M Jun/2025